Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Actemra – Biological Therapy for Rheumatoid Arthritis

Drug (Brand / Generic)

Actemra (tocilizumab)

Company / Licensee

Roche

Therapy Class

Biological response modifier

Product Description

Anti-IL-6 monoclonal antibody

Current Indication

Treatment of rheumatoid arthritis and systemic onset juvenile idiopathic arthritis

Market Sector

Musculo-skeletal disorders (anti-inflammatories)

Development Status

Approved in the US, Europe and Japan
Expand

Go Top